Use of Combinatorial Single Cell Technologies to Drive Deeper Immune Discoveries

We will highlight several applications of fully supported workflows with BD Life Sciences - Biosciences and Illumina that can take you from single cell suspensions to final analyzed data and confirmatory experiments to better understand the human immune system and its role in important biological functions. Multi-omic analysis using the BD Rhapsody™ Single-Cell Analysis System, oligo linked AbSeq antibodies and Illumina Sequencing platforms allowed the discovery of new biomarkers in rare immune cell types leading to high content flow cytometry characterization experiments. We will cover experimental considerations and examples to understand how to use the flexibility of sample tagging to fit different experimental mixtures of sample and cell numbers across various sequencing platforms.

Vishnu Ramani, PhD MBA
Senior Global Product Marketing Manager
BD Life Sciences - Biosciences
 

Dr. Vishnu Ramani has over 16 years of combined academic and industry experience. With over 26 publications, reviews and patents, Dr. Ramani has pioneered the development of several anti-cancer therapies. He is driven to deliver cutting-edge technologies and research tools to support both translational and basic research. Briefly, Dr. Ramani received his PhD in Molecular Physiology and Cellular Biophysics from University of Arkansas for Medical Sciences. After research stints including faculty in Pathology, School of Medicine at the University of Alabama at Birmingham and Senior Scientist at Stanford University, he joined and led the preclinical cancer discovery team at Bolt Biotherapeutics. At BD Biosciences, Dr. Ramani leads the product development for all single cell reagents and leads market development including product marketing efforts.

Steven Hoffman
Senior Segment Manager - Cell Biology
Illumina

Steven is Illumina’s Sr. Segment Manager covering Cell Biology and single-cell applications. He has degrees in Microbiology and Molecular Biology from Michigan State and Texas A&M respectively. He has held various Applications Scientific and Commercial roles over the course of his career; specializing in single cell genomics since 2012.